Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma
Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma
复制标题
DOI：
10.1159/000526521
复制
发表时间：
2022-09-14
期刊：
影响因子：
3.5
通讯作者：
Kudo, Masatoshi
中科院分区：
文献类型：
--
作者：
Hiraoka, Atsushi;Kumada, Takashi;Kudo, Masatoshi
背景/目的：抗血管内皮生长因子(VEGF)单抗引起的尿蛋白不良反应(AEs)是制约不能切除的肝细胞癌(UHCC)系统治疗的因素。结果：在用Logistic回归方法分析启动ATEZ/BEV后12周内尿蛋白相关性AEs的危险因素中，单因素分析显示高血压[优势比(OR)3.54，95%CI：1.28~9.80，P=0.015]和基线尿蛋白尿肌酐比(UPC：>；(OR2.52，95%CI：1.09-5.83，P=0.031)，而尿蛋白早期升高(基线至三周)，每三周尿蛋白升高(Delta UPC/3W)(>；(OR15.80，95%CI：6.15~40.50，P=0.23)(OR14.40，95%CI：4.91~42.00，P=0.23)(OR3.50，95%CI：1.23~99.90，P=0.019)高血压和UPC(>；=0.16)(OR6.12，95%CI2.61~14.30，P=0.23)，Delta UPC/3W(>；=0.23)常见于高血压和/或UPC患者(=0.16)。
Background/Aim: Adverse events (AEs) of urinary protein from monoclonal antibodies against vascular endothelial growth factor (VEGF) are factors that often inhibit systemic therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate risk factors of urinary protein in the early period (= G2) within 12 weeks were defined as significant and related clinical features were analyzed retrospectively.Results: In analyses of risk factors of urinary protein-related AEs during the first 12 weeks after starting Atez/Bev using a logistic regression method, univariate analysis showed positive for hypertension [odds ratio (OR) 3.54, 95%CI: 1.28-9.80, P=0.015] and baseline urinary protein urine creatinine ratio (UPC: >= 0.16) (OR 2.52, 95%CI: 1.09-5.83, P=0.031) as pre-treatment clinical factors, while elevation of urinary protein in the early period (baseline to three weeks) with delta UPC per three weeks (Delta UPC/3W) (>= 0.23) (OR 15.80, 95%CI: 6.15-40.50, P= 0.23) (OR 14.40, 95%CI: 4.91-42.00, P= 0.23) (OR 3.50, 95%CI: 1.23-99.90, P=0.019) were hypertension and UPC (>= 0.16) (OR 6.12, 95%CI 2.61-14.30, P= 0.23), and Delta UPC/3W (>= 0.23) is often seen in patients with hypertension and/or UPC (>= 0.16).